A high-throughput mass spectrometry-based assay for large-scale profiling of circulating human apolipoproteins
Copyright © 2020 Blanchard et al..
Apolipoproteins govern lipoprotein metabolism and are promising biomarkers of metabolic and cardiovascular diseases. Unlike immunoassays, MS enables the quantification and phenotyping of multiple apolipoproteins. Hence, here, we aimed to develop a LC-MS/MS assay that can simultaneously quantitate 18 human apolipoproteins [A-I, A-II, A-IV, A-V, B48, B100, C-I, C-II, C-III, C-IV, D, E, F, H, J, L1, M, and (a)] and determined apoE, apoL1, and apo(a) phenotypes in human plasma and serum samples. The plasma and serum apolipoproteins were trypsin digested through an optimized procedure and peptides were extracted and analyzed by LC-MS/MS. The method was validated according to standard guidelines in samples spiked with known peptide amounts. The LC-MS/MS results were compared with those obtained with other techniques, and reproducibility, dilution effects, and stabilities were also assessed. Peptide markers were successfully selected for targeted apolipoprotein quantification and phenotyping. After optimization, the assay was validated for linearity, lower limits of quantification, accuracy (biases: -14.8% to 12.1%), intra-assay variability [coefficients of variation (CVs): 1.5-14.2%], and inter-assay repeatability (CVs: 4.1-14.3%). Bland-Altman plots indicated no major statistically significant differences between LC-MS/MS and other techniques. The LC-MS/MS results were reproducible over five repeated experiments (CVs: 1.8-13.7%), and we identified marked differences among the plasma and serum samples. The LC-MS/MS assay developed here is rapid, requires only small sampling volumes, and incurs reasonable costs, thus making it amenable for a wide range of studies of apolipoprotein metabolism. We also highlight how this assay can be implemented in laboratories.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Journal of lipid research - 61(2020), 7 vom: 13. Juli, Seite 1128-1139 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Blanchard, Valentin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Apolipoproteins |
|---|
| Anmerkungen: |
Date Completed 11.08.2021 Date Revised 11.08.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1194/jlr.D120000835 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309872960 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309872960 | ||
| 003 | DE-627 | ||
| 005 | 20231225134849.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1194/jlr.D120000835 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1032.xml |
| 035 | |a (DE-627)NLM309872960 | ||
| 035 | |a (NLM)32404332 | ||
| 035 | |a (PII)S0022-2275(20)43589-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Blanchard, Valentin |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A high-throughput mass spectrometry-based assay for large-scale profiling of circulating human apolipoproteins |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.08.2021 | ||
| 500 | |a Date Revised 11.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Blanchard et al. | ||
| 520 | |a Apolipoproteins govern lipoprotein metabolism and are promising biomarkers of metabolic and cardiovascular diseases. Unlike immunoassays, MS enables the quantification and phenotyping of multiple apolipoproteins. Hence, here, we aimed to develop a LC-MS/MS assay that can simultaneously quantitate 18 human apolipoproteins [A-I, A-II, A-IV, A-V, B48, B100, C-I, C-II, C-III, C-IV, D, E, F, H, J, L1, M, and (a)] and determined apoE, apoL1, and apo(a) phenotypes in human plasma and serum samples. The plasma and serum apolipoproteins were trypsin digested through an optimized procedure and peptides were extracted and analyzed by LC-MS/MS. The method was validated according to standard guidelines in samples spiked with known peptide amounts. The LC-MS/MS results were compared with those obtained with other techniques, and reproducibility, dilution effects, and stabilities were also assessed. Peptide markers were successfully selected for targeted apolipoprotein quantification and phenotyping. After optimization, the assay was validated for linearity, lower limits of quantification, accuracy (biases: -14.8% to 12.1%), intra-assay variability [coefficients of variation (CVs): 1.5-14.2%], and inter-assay repeatability (CVs: 4.1-14.3%). Bland-Altman plots indicated no major statistically significant differences between LC-MS/MS and other techniques. The LC-MS/MS results were reproducible over five repeated experiments (CVs: 1.8-13.7%), and we identified marked differences among the plasma and serum samples. The LC-MS/MS assay developed here is rapid, requires only small sampling volumes, and incurs reasonable costs, thus making it amenable for a wide range of studies of apolipoprotein metabolism. We also highlight how this assay can be implemented in laboratories | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a assay development | |
| 650 | 4 | |a isotopic labeling | |
| 650 | 4 | |a lipid metabolism | |
| 650 | 4 | |a lipoprotein metabolism | |
| 650 | 4 | |a metabolic disease | |
| 650 | 4 | |a plasma lipid | |
| 650 | 4 | |a proteomics | |
| 650 | 4 | |a serum lipid | |
| 650 | 7 | |a Apolipoproteins |2 NLM | |
| 700 | 1 | |a Garçon, Damien |e verfasserin |4 aut | |
| 700 | 1 | |a Jaunet, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Chemello, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Billon-Crossouard, Stéphanie |e verfasserin |4 aut | |
| 700 | 1 | |a Aguesse, Audrey |e verfasserin |4 aut | |
| 700 | 1 | |a Garfa, Aya |e verfasserin |4 aut | |
| 700 | 1 | |a Famchon, Gilles |e verfasserin |4 aut | |
| 700 | 1 | |a Torres, Amada |e verfasserin |4 aut | |
| 700 | 1 | |a Le May, Cédric |e verfasserin |4 aut | |
| 700 | 1 | |a Pichelin, Matthieu |e verfasserin |4 aut | |
| 700 | 1 | |a Bigot-Corbel, Edith |e verfasserin |4 aut | |
| 700 | 1 | |a Lambert, Gilles |e verfasserin |4 aut | |
| 700 | 1 | |a Cariou, Bertrand |e verfasserin |4 aut | |
| 700 | 1 | |a Hadjadj, Samy |e verfasserin |4 aut | |
| 700 | 1 | |a Krempf, Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Bach-Ngohou, Kalyane |e verfasserin |4 aut | |
| 700 | 1 | |a Croyal, Mikaël |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of lipid research |d 1960 |g 61(2020), 7 vom: 13. Juli, Seite 1128-1139 |w (DE-627)NLM000005878 |x 1539-7262 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2020 |g number:7 |g day:13 |g month:07 |g pages:1128-1139 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1194/jlr.D120000835 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2020 |e 7 |b 13 |c 07 |h 1128-1139 | ||